Jinzi Wu
Algemeen Directeur bij ASCLETIS PHARMA INC.
Vermogen: 92 M $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Judy Hejingdao Wu | F | 50 |
Ascletis Pharmaceuticals Co., Ltd.
Ascletis BioScience Co., Ltd.
Gannex LLC
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | 10 jaar |
Cheng Li | M | 67 |
Nanjing University
| 46 jaar |
David Happel | M | 62 | 2 jaar | |
Elizabeth Grammer | F | 60 | 3 jaar | |
Lin Hua | F | 50 | 6 jaar | |
Yizhen Wei | M | 49 | 6 jaar | |
Joshua Zhongbao | M | - | 6 jaar | |
Elizabeth Rozek | F | 53 | 1 jaar | |
Zhi Ming Cheng | M | 62 |
Nanjing University
| 42 jaar |
Victor Shi | M | - |
The BayHelix Group
| - |
Jiong Gu | M | 51 | 6 jaar | |
Guo-Liang Yu | M | 62 |
The BayHelix Group
| - |
Eduardo Bruno Martins | M | 61 | 3 jaar | |
Yan Yuemei | F | - | - | |
Yun Zhang | F | 40 |
The BayHelix Group
| - |
Yuan Hua Ding | M | 61 |
The BayHelix Group
| - |
Handan He | M | - | 5 jaar | |
Yi You Chen | M | - |
The BayHelix Group
| - |
Marietta Wu | M | 56 |
The BayHelix Group
| - |
Zhengqing Li | M | - | 5 jaar | |
Ming Fai Chung | M | 45 | 2 jaar | |
Wei Fu | M | 42 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
Ming Guo | M | 67 |
The BayHelix Group
| - |
Jian Fan | M | 67 |
Nanjing University
| 41 jaar |
John Gargiulo | M | - | 2 jaar | |
James Xue | M | 54 |
The BayHelix Group
| - |
Yi Ning Zhao | M | 53 |
The BayHelix Group
| 13 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Steven Gillis | M | 71 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 13 jaar |
Joseph Oriti | M | 44 | - | |
Ulrich Lehner | M | 78 | 13 jaar | |
Ji Shun Liu | M | 67 |
Nanjing University
| 9 jaar |
Philippe Calais | M | 65 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 jaar |
Anthony Rimac | M | 60 | 1 jaar | |
Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 jaar |
Rolf M. Zinkernagel | M | 80 | 15 jaar | |
Pierre Landolt | M | 77 | 22 jaar | |
Giancarlo Mocchi | M | 84 | 3 jaar | |
Daniel Vasella | M | 70 | 17 jaar | |
Run Yu | M | 68 |
Nanjing University
| 18 jaar |
Edward V. Fritzky | M | 73 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 8 jaar |
Daniel McEvers Mahoney | M | - |
University of Arizona
| 8 jaar |
Jin Xing Qi | M | 62 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
Nicole T. Sweetland | M | - |
University of Arizona
| 4 jaar |
Zhen Hai Liang | M | 59 |
Nanjing University
| 7 jaar |
Long Quan Pan | M | 60 |
Nanjing University
| 6 jaar |
Christine L. Salvesen | F | - |
University of Arizona
| 6 jaar |
Ayani Kurussi Ravi Nedungadi | M | 65 | - | |
Stephen G. Sudovar | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 jaar |
Bradley Mitchell | M | - |
University of Arizona
| 7 jaar |
Haichuan Qian | M | - |
Nanjing University
| 7 jaar |
Dong Xiao Zhang | M | 58 |
University of Arizona
| 3 jaar |
Peter Kornicker | M | - | 20 jaar | |
Wei Dong Li | M | 56 |
Nanjing University
| 6 jaar |
Bosheng Zhou | M | 59 |
Nanjing University
| 7 jaar |
Mathew Cherian | M | 59 | 30 jaar | |
Hai Sang | M | 67 |
Nanjing University
| 6 jaar |
Subhash Raghunath Gupte | M | 85 | 25 jaar | |
Paulo Costa | M | 73 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 6 jaar |
Peter Burckhardt | M | - | - | |
Alexandre F. Jetzer-Chung | M | 83 | 15 jaar | |
Wayne P. Yetter | M | 78 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | - |
Gordon Ringold | M | 73 | 14 jaar | |
Peter Atadja | M | 64 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 24 jaar |
Chad W. Souvignier | M | - |
University of Arizona
| 5 jaar |
James Young | M | 71 | 13 jaar | |
Richard Rodgers | M | 57 | 9 jaar | |
Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 jaar |
Bonabes-Olivier de Rougé | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 jaar |
Jin Qian Jiang | M | - |
Nanjing University
| 4 jaar |
Lung Yun Tong | M | 61 |
Nanjing University
| 4 jaar |
Xian Xin Zhao | M | 54 |
Nanjing University
| 4 jaar |
Xiao Hu Yang | F | 53 |
Nanjing University
| 4 jaar |
Xian Lin Sun | M | - |
Nanjing University
| 4 jaar |
Wei Ying Zhu | F | 57 |
Nanjing University
| 4 jaar |
Hai Wen He | F | 54 |
University of Arizona
| 2 jaar |
Adam Brooks | M | - |
University of Arizona
| 4 jaar |
Natalie Burkart | F | - |
University of Arizona
| 4 jaar |
Chang Sheng Xu | M | 61 |
Nanjing University
| 4 jaar |
Justin Keith Gard | M | - |
University of Arizona
| 5 jaar |
Shawn Davis | M | - |
University of Arizona
| 4 jaar |
Jason P. Ley | M | - |
University of Arizona
| 3 jaar |
Xin Ming Mu | M | 67 |
Nanjing University
| 4 jaar |
Yi Zhang | F | 57 |
Nanjing University
| 4 jaar |
Guo Xiao Yong | M | - |
Nanjing University
| 4 jaar |
Sri Nagarajan | M | - |
University of Arizona
| 2 jaar |
Wencheng Zhou | M | 48 |
Nanjing University
| 4 jaar |
Jonathan A. Firestein | M | - |
University of Arizona
| 4 jaar |
Matthew Wild | M | - |
University of Arizona
| 4 jaar |
Walter H. Stryker | M | - |
Nanjing University
| 1 jaar |
Peter W. Rutti | M | - |
University of Arizona
| 4 jaar |
Tim Jia | M | - |
Nanjing University
| 4 jaar |
Bai Chun Xiao | M | 76 |
Nanjing University
| 4 jaar |
Yu Shan Wan | M | 53 |
Nanjing University
| 4 jaar |
Aaron Todd Switz | M | - |
University of Arizona
| 4 jaar |
Brandon Nagler | M | - |
University of Arizona
| 4 jaar |
Wei Xiao | F | 54 |
Nanjing University
| 4 jaar |
Zhi Huai Xu | M | 67 |
Nanjing University
| 4 jaar |
Yufeng Wei | M | 55 |
Nanjing University
| 4 jaar |
Michael Daniel Roth | M | - |
University of Arizona
| 4 jaar |
Jun Zhou | M | 56 |
Nanjing University
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 44 | 44.00% |
China | 33 | 33.00% |
Kaaimaneilanden | 10 | 10.00% |
Zwitserland | 8 | 8.00% |
Canada | 4 | 4.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties